煤矿智能化是推动煤炭行业高质量发展的核心技术支撑，也是行业转型升级的必由之路。煤矿智能化建 设不仅有助于提升煤炭产业的整体竞争力，还能有效保障能源安全稳定供应，为构建新型能源体系奠定 坚实基础。 揭榜赛马，挑战无人化采煤"深水区" 2024年，中国煤炭科工创新提出的"地面规划采煤、装备自动执行、面内无人作业"的无人化采煤新模 式，推动我国无人化采煤关键技术研发与应用领域取得重大突破，开创煤矿无人化开采先河。2021年国 家能源局、国家煤矿安全监察局确定的71处（含5处露天煤矿）国家首批智能化示范建设煤矿中有39处 由中国煤炭科工提供技术支撑，占比55%；2023年全国煤矿采煤工作面智能创新大赛28个获奖工作面由 中国煤炭科工提供技术支撑，占比39%，2024年34个获奖工作面由中国煤炭科工提供技术支撑，占比 46%，引领了煤矿无人化智能开采行业发展的新态势。 2020年2月，国家八部门联合印发的《关于加快煤矿智能化发展的指导意见》提出，到2025年，综采工 作面内达到少人、无人操作。此时距离中国煤炭科工建成首个"有人巡视、无人操作"可视化远程干预智 能化采煤模式已经过去5年。5年间可视化远程干预模式已在我国大 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

证券代码：300832 证券简称：新产业 公告编号：2025-047 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 国家知识产权局颁发的1项《发明专利证书》，现将本次取得的发明专利具体情 况公告如下： 发明名称：抗PIC的抗体、试剂盒及检测PIC的方法 中国专利号：ZL202210547227.2 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：张云、高莉、甘兴、万谦、王燕梅、赵莉 专利申请日：2022年05月19日 授权公告日：2025年05月27日 上述专利保护技术为公司自主研发，本发明提供了一种新的抗纤溶酶-α2纤 溶酶抑制剂复合物（PIC）的抗体，该抗体对PIC抗原的亲和力和特异性更高，因 而利用该抗体进行双抗体夹心法检测样品时，能够实现一步法检测，在特异性和 准确性高的同时，大大缩短了检测时间，提高了检测速度和效率。 本次取得的发明专利不会对公司目前的经营状况产生重大影响，但有利于完 善公司知识产权体系， ...

登录新浪财经APP 搜索【信披】查看更多考评等级 华夏基金管理有限公司（以下简称"本基金管理人"）旗下管理的华夏中证信息技术应用创新产业交易型 开放式指数证券投资基金（基金简称：华夏中证信息技术应用创新产业ETF，扩位简称：信创ETF，基 金代码：562570，以下简称"本基金"）近期规模变动较大，该基金标的指数权重股停牌，无法及时调整 投资组合，可能导致本基金跟踪误差及跟踪偏离度扩大，敬请投资者关注相关风险并谨慎做出投资决 策。 华夏基金管理有限公司关于以通讯方式召开 华夏新锦升灵活配置混合型证券投资基金 基金份额持有人大会的第二次提示性公告 根据华夏基金管理有限公司（以下简称"本基金管理人"）于2025年6月6日发布的《华夏基金管理有限公 司关于以通讯方式召开华夏新锦升灵活配置混合型证券投资基金基金份额持有人大会的公告》，本基金 管理人决定以通讯方式召开华夏新锦升灵活配置混合型证券投资基金（以下简称"本基金"）的基金份额 持有人大会，审议《关于华夏新锦升灵活配置混合型证券投资基金持续运作的议案》。为了使本次基金 份额持有人大会顺利召开，现将具体事宜提示如下： 一、召开会议基本情况 本基金的联接基金华夏中证 ...

Core Viewpoint - Shenzhen is positioning itself as a leader in the new track of "new quality productivity," focusing on hard technology innovations such as artificial intelligence, drones, and new energy vehicles, which are crucial for the global industrial landscape transformation [1][3]. Group 1: Technological Advancements - Shenzhen's R&D investment reached 223.66 billion yuan, growing by 18.9%, marking nine consecutive years of double-digit growth, which supports breakthroughs in hard technology [3]. - Major technological showcases at recent exhibitions included BYD's "megawatt flash charging" technology, allowing for a one-minute charge to achieve a 100-kilometer range, addressing user concerns about range anxiety [3]. - Huawei unveiled significant products like the HUAWEI MateBook Fold and HUAWEI MateBook Pro at the global AI terminal exhibition, while DJI showcased the new Matrice 4 series drones with advanced AI detection capabilities [4]. Group 2: Application of Technology - The trend of technology rapidly transitioning from exhibition to real-life applications is evident, with AI and drones being integrated into various sectors such as smart homes, logistics, and emergency services [5][6]. - Shenzhen plans to open 100 application scenarios annually to enhance the matching of supply and demand, facilitating product development and technology iteration [6]. Group 3: Ecosystem Development - The exhibitions reflect a shift from merely showcasing products to presenting an entire ecosystem, highlighting the collaboration between technology and industry [7]. - The establishment of the Shenzhen AI Glasses Industry Alliance aims to integrate resources across the AI glasses sector, promoting innovation and scaling [8][9]. - Policies supporting the development of these industries include the launch of investment funds for AI terminals and robotics, indicating a strong commitment to fostering long-term capital investment [9]. Group 4: Future Outlook - The combination of hard technology breakthroughs, accelerated application scenarios, and efficient industrial ecosystem collaboration forms the "innovation triangle," which is central to Shenzhen's new quality productivity strategy [9].

Core Insights - The article discusses the evolution and current state of intellectual property asset-backed securities (ABS) in China, highlighting its significance in financing for small and medium-sized technology enterprises [1][2][10] - It emphasizes the growth of the market, with a cumulative issuance scale exceeding 200 billion yuan by June 2025, and the increasing recognition of intellectual property as a valuable asset [1][10] Market Development - The first intellectual property ABS in China was approved in December 2018, and as of June 5, 2023, at least 12 intellectual property ABS have been issued this year, totaling 1.356 billion yuan [1] - In 2024, the issuance of intellectual property ABS products reached 57, with a total scale of 9.806 billion yuan, marking a year-on-year increase of 25.97% [2] Institutional Concentration - The majority of intellectual property ABS issuers are small loan companies, commercial factoring companies, and financing leasing companies, with a high concentration among the top five issuers, accounting for 74.68% of the total issuance [2][4] - Shenzhen's small loan companies dominate the market, with Shenzhen Zhongxiaodang and Shenzhen Gaoxin Investment holding a combined market share of 58.80% [2][4] Product Characteristics - Intellectual property ABS typically have smaller issuance sizes, around 100 million yuan, and primarily serve smaller enterprises, reflecting a certain degree of inclusive finance [4][8] - The underlying asset types for intellectual property ABS are diversifying, including agricultural IP, new energy vehicle IP, and digital currency IP [5] Financing Channels - The article highlights the exploration of cross-border financing channels for intellectual property ABS, particularly in the Greater Bay Area, allowing companies to leverage their intellectual property for overseas financing [5][6] Operational Standards - The operational model for intellectual property ABS has become more standardized, with established processes for small loan companies to provide funding and guarantee enhancements [7][8] - The Shenzhen model of intellectual property ABS is characterized by state-owned enterprises leading the initiative, government subsidies reducing financing costs, and active market participation [10][12] Market Challenges - Despite the growth, the intellectual property ABS market is still in its early stages, with limited investor recognition and liquidity issues affecting issuance and trading [13][14] - Challenges include the lack of unified standards for intellectual property valuation and the need for improved risk management practices [14][15]

Core Viewpoint - The Guangzhou Marine Technology Innovation Industry Development Conference aims to accelerate the development of marine new productivity and establish Guangzhou as a hub for marine innovation and development [2][3]. Group 1: Government Initiatives - Guangzhou is focusing on building a modern industrial system characterized by the "12218" framework, emphasizing sectors such as ports, shipping, energy, pharmaceuticals, and tourism [2]. - The government plans to optimize the business environment and implement marine industry planning, investment policies, and resource guarantees to attract entrepreneurs and scientists [2][3]. Group 2: Strategic Collaborations - The conference featured the launch of the first national marine government-industry-research-academia exchange platform, "Guanghaihui," and strategic cooperation agreements were signed with various institutions [3]. - The event showcased 20 cutting-edge marine technology innovations, highlighting Guangzhou's commitment to marine economic development and investment promotion [3]. Group 3: Economic Potential - Guangzhou's marine industry is comprehensive, with a leading position in marine economic output and technological innovation capabilities, which are seen as unique advantages for driving marine technology and industry development [3].

二、 公司控股股东及其一致行动人股份累计质押的情况 截至公告披露日，公司控股股东西藏新产业及实际控制人翁先定先生所持质 1 证券代码：300832 证券简称：新产业 公告编号：2025-046 深圳市新产业生物医学工程股份有限公司 关于控股股东部分质押股份办理延期购回手续的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 公司控股股东西藏新产业投资管理有限公司（以下简称"西藏新产业"）的函告， 获悉西藏新产业所持有的公司 660 万股（含补充质押 110 万股）质押股份办理了 延期购回手续。具体事项如下： 上述办理延期购回手续的质押股份相关情况请参见公司分别于 2024 年 7 月 30 日、2025 年 4 月 10 日在巨潮资讯网披露的《关于控股股东部分股份办理质押 及解除质押的公告》（公告编号：2024-052）、《关于控股股东部分股份办理补 充质押的公告》（公告编号：2025-017）。 股东 名称 是否为 控股股 东或第 一大股 东及其 一致行 动人 办理延期 购回的质 押股份数 ...

Performance Review - Company reported 1Q25 financial data: revenue of 5.876 billion yuan, a year-on-year increase of 14.6%, gross profit of 1.428 billion yuan, a year-on-year increase of 11.8%, and net profit attributable to shareholders of 635 million yuan, a year-on-year increase of 23.2%, meeting expectations [1]. Development Trends Mining Equipment - Domestic demand remains resilient, with positive outlook for overseas expansion of mining trucks. Domestic coal prices are in a downward trend due to weak demand. Current demand for tunneling machines and wide-body trucks is strong, while hydraulic support prices are under intense competition. The company expects good growth for overseas wide-body trucks and large mining trucks, driven by product upgrades and reduced overall user costs, indicating significant long-term growth potential in large mining trucks and related aftermarket [1]. Logistics Equipment - Demand for port machinery is on the rise, with expansion of new products overseas. Starting in 2023, global demand for port equipment is recovering, with full orders for large port machinery and gradually strengthening order profitability. Exports of small port machinery products remain robust in Asia, Africa, and Latin America. Over the past three years, the company has aggressively expanded new products like telescopic forklifts in the European and American markets, currently producing in India to address tariff issues. The company is optimistic about the trend towards electrification of small port machinery and the continued expansion of new products overseas [1]. Oil and Gas Equipment - Demand and profitability are expected to recover. In 2024, revenue and profitability declined due to major clients' cost-cutting measures. The company anticipates marginal recovery in industry demand in 2025, with strengthened internal management to restore market share [2]. New Industries - Focus on cost reduction and efficiency improvement, expanding overseas application scenarios. In 2024, the company will enhance management reforms for new industries, readjusting businesses with intense competition and limited profitability. It is expected that operating losses in new industries will significantly narrow in 2025, optimizing the efficiency and return rate of existing assets [2]. Profit Forecast and Valuation - The company maintains the 2025 EPS forecast at 0.70 yuan and introduces the 2026 EPS forecast at 0.81 yuan. The current stock price corresponds to 7.9x/6.7x P/E for 2025/2026. Considering the improvement prospects in new industry profitability, the target price is raised by 25% to 7.10 HKD, corresponding to 9.5x/8.1x P/E for 2025/2026, indicating a 21% upside potential, maintaining an outperform rating [2].

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a mixed performance, with a recent decline despite a slight year-to-date increase, indicating volatility in the healthcare sector [1]. Group 1: Index Performance - The CSI Healthcare Equipment and Services Index decreased by 0.29% to 13723.04 points, with a trading volume of 15.888 billion yuan [1]. - Over the past month, the index has increased by 5.01%, but it has decreased by 3.91% over the last three months, and it has risen by 0.54% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these companies [1]. - The top ten weighted companies in the index include Mindray Medical (9.76%), Aier Eye Hospital (7.89%), and United Imaging Healthcare (7.59%) [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (60.77%) and the Shanghai Stock Exchange (39.23%) [1]. Group 3: Sample Adjustment and Fund Tracking - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]. - Public funds tracking the healthcare index include several funds from Southern Asset Management and Tianhong Asset Management, among others [2].